Novo Nordisk receives European Commission approval of Wegovy pill as first oral GLP-1 for weight management
The European Commission (EC) has granted marketing authorisation for Wegovy pill (once-daily oral semaglutide 25 mg) for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity.
July 16, 2026
This follows the positive opinion issued by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in May 2026.
The Wegovy pill approval is a landmark moment in the treatment of obesity in Europe, making it the first GLP-1 receptor agonist available in tablet form for weight management across all European Union member states. It marks the fifth regulatory approval of Wegovy pill, after the US, UK, UAE and Bahrain, states Novo Nordisk.
“Today’s European Commission approval of Wegovy as a once-daily pill brings another important treatment option to people living with obesity,” says Mike Doustdar, president and CEO of Novo Nordisk. “Obesity is a serious chronic disease, and choice can make a real difference. For many people, a tablet may be a simpler and more acceptable way to start and continue treatment. This is more than a regulatory milestone – it is a step toward better and lasting health for people with obesity and a strong societal response to one of Europe’s most significant health challenges.”
The European Commission (EC) also granted approval for Wegovy 7.2 mg injection in a single-dose pen for people living with obesity.
Wegovy pill is currently available in the US, UK and UAE, and Novo Nordisk is committed to launching Wegovy pill in more countries in the second half of 2026.
Published: July 16, 2026
